MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from at the
market offering, net of...
$15,392K
Proceeds from exercise of
stock options
$279K
Net cash provided by
(used in) financing...
$15,671K
Net change in cash,
cash equivalents,...
-$6,498K
Canceled cashflow
$15,671K
Loss (gain) on change
in fair value of cvr...
$13,800K
Stockbased compensation
expense
$2,423K
Accounts receivable
-$854K
Depreciation and
amortization
$615K
Accounts payable
$310K
Noncash lease expense
$235K
Net cash used in
operating activities
-$22,135K
Canceled cashflow
$18,237K
Net cash used in
investing activities
-$27K
Effect of exchange rate
changes on cash
-$7K
Total revenues
$78K
Net loss
-$39,182K
Canceled cashflow
$78K
Accrued expenses and
other liabilities
-$850K
Prepaid expenses and
other assets
$246K
Gain on change in
warrant liability
-$94K
Purchases of property and
equipment
$27K
Other expense
(income), net
-$12,683K
Research and
development-Descartes08For MG
$12,135K
General and
administrative
$7,114K
Research and
development-Research And Development...
$3,828K
Research and
development-Research And Development...
$1,969K
Research and
development-Research And Development...
$949K
Research and
development-Early Stage Programs
$355K
Research and
development-Descartes08For...
$227K
Back
Back
Cash Flow
Cartesian Therapeutics, Inc. (RNAC)
Cartesian Therapeutics, Inc. (RNAC)
source: myfinsight.com